(Q35036495)

5 August 2017

1 reference

7 January 2023

1 reference

title

Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review (English)

1 reference

5 August 2017

main subject

macular retinal edema

1 reference

18 August 2020

retinal vein occlusion

1 reference

intravitreal administration

7 January 2023

1 reference

patient safety

1 reference

central retinal vein occlusion

1 reference

inferred from abstract

author

Christine Schmucker

series ordinal

6

1 reference

5 August 2017

Amelie Pielen

1

0 references

Nicolas Feltgen

series ordinal

2

object named as

Nicolas Feltgen

1 reference

5 August 2017

5

Bernd Junker

1 reference

5 August 2017

4

Josep Callizo

1 reference

5 August 2017

3

Christin Isserstedt

1 reference

5 August 2017

language of work or name

English

0 references

publication date

25 October 2013

11 references

5 August 2017

5 March 2019

13 March 2019

19 March 2019

22 March 2019

25 April 2019

17 June 2019

25 June 2019

18 August 2020

26 October 2022

7 January 2023

11 references

5 August 2017

5 March 2019

13 March 2019

19 March 2019

22 March 2019

25 April 2019

17 June 2019

25 June 2019

18 August 2020

26 October 2022

7 January 2023

8

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

e78538

1 reference

Creative Commons Attribution 4.0 International

5 August 2017

copyright license

10 references

5 March 2019

13 March 2019

19 March 2019

22 March 2019

25 April 2019

17 June 2019

25 June 2019

18 August 2020

26 October 2022

on focus list of Wikimedia project

7 January 2023

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Economic considerations of macular edema therapies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...]

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

SCORE Study report 3: study design and baseline characteristics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Pegaptanib sodium for macular edema secondary to central retinal vein occlusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

The epidemiology of age-related macular degeneration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

VEGF-Trap: a VEGF blocker with potent antitumor effects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion

8 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0078538

Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3808377

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group

25 October 2018

1 reference

12 December 2020

Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group

1 reference

12 December 2020

Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone

1 reference

12 December 2020

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein

1 reference

12 December 2020

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study

1 reference

12 December 2020

Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results

1 reference

12 December 2020

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial

1 reference

12 December 2020

Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study

1 reference

12 December 2020

Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0078538

Identifiers

DOI

1 reference

5 August 2017

0 references

1 reference

5 August 2017

1 reference